Navigation Links
Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008
Date:6/24/2008

ceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that include the word "potential". Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management's expectations and affect the forward-looking statements include but are not be limit
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
2. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
3. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
4. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
5. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
6. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
7. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
8. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
9. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ) ... report "Cytogenetics - Technologies, Markets and Companies" ... deals with cytogenetics in a broader sense rather ... chromosome structure and identify abnormalities related to disease. ... also referred to as molecular cytogenetics. The scope ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
Breaking Biology Technology:New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... New Opportunity to Serve Pharmaceutical Partner Interest for ... ... Transgenomic, Inc. (OTC,Bulletin Board: TBIO), a global genetic analysis ... laboratory services agreement,with the Guangzhou Family Planning Center in Guangzhou, ...
... NEWTON, Mass., March 31 Tryton Medical, Inc., ... treatment of,bifurcation lesions announced today that it has ... Two new investors, PTV Sciences and RiverVest Venture,Partners ... Rick Anderson,from PTV and Jay Schmelter from RiverVest ...
... 31 ExonHit Therapeutics, a drug,and diagnostic discovery company, ... join the Management Board on April 1st,2008. At the ... Board, until a new CEO is appointed., Philippe ... 2002,and has been a member of its Management Board ...
Cached Biology Technology:Transgenomic Opens Pharmacogenomics Laboratory in China 2Transgenomic Opens Pharmacogenomics Laboratory in China 3Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3ExonHit Appoints a New Management Board 2ExonHit Appoints a New Management Board 3ExonHit Appoints a New Management Board 4
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Biology of Reproduction includes a special paper by a ... mice results in shorter life expectancy and reduced body ... maternal age in women, such as abnormal numbers of ... potential negative effects on offspring from delayed motherhood have ...
... of Pennsylvania School of Medicine have developed an animal ... in humans. From this, they hope to develop new ... among the most lethal of cancers, with a one-year ... percent of patients, according to the National Cancer Institute. ...
... The World Health Organization (WHO) and the United Nations Children's ... halve deaths from measles, a leading vaccine-preventable killer, by the ... 39%, from 873 000 in 1999 to an estimated 530 ... the region with the highest burden of the disease, where ...
Cached Biology News:Disease progression model of pancreatic cancer developed by Penn researchers 2Disease progression model of pancreatic cancer developed by Penn researchers 3Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Biology Products: